(Q37345134)

19 August 2017

1 reference

title

Human papillomavirus vaccine and cervical cancer prevention (English)

1 reference

19 August 2017

1 reference

cervix uterine cancer

1 reference

Ana Oaknin

1

1 reference

19 August 2017

Ma Pilar Barretina

series ordinal

2

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Clinical and Translational Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

10

1 reference

19 August 2017

issue

12

1 reference

19 August 2017

page(s)

804-811

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-008-0293-7

19 August 2017

exact match

0 references

cites work

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-008-0293-7

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 January 2018

1 reference

12 December 2020

The future of vaccines for cervical cancer

1 reference

12 December 2020

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

1 reference

12 December 2020

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

12 December 2020

HPV vaccination--more answers, more questions

1 reference

12 December 2020

The global health burden of infection-associated cancers in the year 2002

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

12 December 2020

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

12 December 2020

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

1 reference

12 December 2020

Prevention strategies against the human papillomavirus: the effectiveness of vaccination

1 reference

12 December 2020

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

12 December 2020

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

1 reference

12 December 2020

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

12 December 2020

Epidemiology of Genital Human Papillomavirus Infection

1 reference

12 December 2020

Introducing HPV vaccine in developing countries--key challenges and issues

1 reference

12 December 2020

Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002

1 reference

12 December 2020

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

12 December 2020

Cervical cancer screening: which techniques should be used and why?

1 reference

12 December 2020

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

12 December 2020

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

12 December 2020

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

12 December 2020

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

12 December 2020

Health and economic implications of HPV vaccination in the United States

1 reference

12 December 2020

The natural history of cervical HPV infection: unresolved issues

1 reference

12 December 2020

Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy

1 reference

12 December 2020

Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia

1 reference

12 December 2020

Immunobiology of HPV and HPV vaccines

1 reference

12 December 2020

Impact of the human papilloma vaccine on cervical cancer

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

12 December 2020

Risk factors for rapid-onset cervical cancer

1 reference

12 December 2020

Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins

1 reference

12 December 2020

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

12 December 2020

10.1007/S12094-008-0293-7

Identifiers

DOI

1 reference

19 August 2017

1 reference